Cargando…
Lipoprotein‐Associated Phospholipase A(2) Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease
BACKGROUND: We evaluated lipoprotein‐associated phospholipase A(2) (Lp‐PLA (2)) activity in patients with stable coronary heart disease before and during treatment with darapladib, a selective Lp‐PLA (2) inhibitor, in relation to outcomes and the effects of darapladib in the STABILITY trial. METHODS...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937279/ https://www.ncbi.nlm.nih.gov/pubmed/27329448 http://dx.doi.org/10.1161/JAHA.116.003407 |